In chronic lymphocytic leukemia, the number of B cells is abnormally elevated. The lymph nodes are swollen due to the insertion of B cells. The active substance “Ibrutinib” blocks the interaction of BTK (Brutone Tyrosine Kinase) and transcription factor NFkB in the B cells, which enables cell death and thereby reduces their number. As more and more B-cells and also BTK are produced, a continuous intake of the drug is necessary to reduce the number of B-cells.
Project description:
Content: 5 illustrations
Utilization: printed information folder for sales force
Specifications: Print, DIN A5 / 300dpi
Client: Sir Prise & Lady Buy / Janssen Swiss
The rights of use of the illustrations shown are with the respective clients. The images are protected with a watermark.
